<DOC>
	<DOCNO>NCT02891551</DOCNO>
	<brief_summary>The study design prospective , non-interventional , observational single arm study . A minimum 150 patient recruit approximately 30 haematology/oncology site Netherlands . In case , decision treat patient azacitidine already make prior decision enter subject study . Recruitment continue end June 2015 , provide minimum 150 patient include study . When date reach , patient azacitidine continue follow last patient enrol follow 12 month .</brief_summary>
	<brief_title>An Observational Post Authorisation Study Evaluate Safety Efficacy Patients Receiving Azacitidine Daily Clinical Practice Netherlands</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients 18 year age understand voluntarily sign informed consent form . Patients treat azacitidine accordance register indication clinical practice . Refusal participate study . Participation interventional clinical study . Patients previously treat azacitidine except give induction therapy maximum three course . Women pregnant breastfeeding . Hypersensitivity active substance excipients . Advanced malignant hepatic tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>Acute</keyword>
	<keyword>Observational</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>OCEAN</keyword>
	<keyword>Netherlands</keyword>
	<keyword>azacitidine</keyword>
</DOC>